KURE KraneShares MSCI All China Health Care Index ETF
Quote as of Aug 26, 2026 19:52 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 19.07 | Day Range | 19.05 – 19.24 |
| 52-Week Range | 14.38 – 21.88 | Volume | 15.20K |
| Avg Volume | 48.14K | AUM | $110.6M (Aug 27, 2026) |
| Expense Ratio | 0.79% | Yield (TTM) | 3.74% |
| NAV | 19.06 | Premium/Discount | +0.19% indicative |
| Inception | Jan 31, 2018 | Holdings | 53 |
| Issuer | KraneShares | Exchange | AMEX |
| Category | Healthcare | Index Tracked | Not stated in source data |
| CUSIP | 500767835 | ISIN | US5007678353 |
| Management | Not stated in source data | ||
About this ETF
This exchange-traded fund will allocate at least 80% of its net assets, including any capital acquired through borrowing for investment purposes, to financial instruments that are components of its underlying index or exhibit similar economic characteristics. The reference index is a market capitalization-weighted measure, adjusted for free float, and applies a 10/40 Constraint. Its objective is to gauge the equity market performance of Chinese enterprises within the healthcare sector. This fund does not maintain a diversified portfolio.
Description from the fund data provider · profile as of Aug 27, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | +9.88% | +18.69% | +4.70% | +12.07% | -7.16% | +3.44% | -11.68% | — | -2.97% |
| Total return | +9.90% | +18.71% | +4.71% | +12.09% | -3.49% | +5.46% | -8.22% | — | -0.69% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Aug 26, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.79% | Annual cost of a $10,000 investment | $79.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Aug 22, 2026 — portfolio reporting date from the data provider; holdings are not live positions. 48 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | BEONE MEDICINES LTD-H | 6160.HK | 9.37% | 354.82K | $10.3M |
| 2 | INNOVENT BIOLOGICS INC | 1801.HK | 9.34% | 788.00K | $10.3M |
| 3 | WUXI BIOLOGICS CAYMAN INC | 2269.HK | 8.54% | 1.45M | $9.4M |
| 4 | WUXI APPTEC CO LTD-A | 603259.SS | 5.57% | 253.32K | $6.1M |
| 5 | SHENZHEN MINDRAY BIO-MEDIC-A | 300760.SZ | 4.16% | 199.66K | $4.6M |
| 6 | CSPC PHARMACEUTICAL GROUP LT | 1093.HK | 3.73% | 3.50M | $4.1M |
| 7 | SINO BIOPHARMACEUTICAL | 1177.HK | 3.73% | 5.75M | $4.1M |
| 8 | JIANGSU HENGRUI PHARMACEUT-A | 600276.SS | 3.59% | 556.81K | $4.0M |
| 9 | AKESO INC | 9926.HK | 3.55% | 340.00K | $3.9M |
| 10 | WUXI APPTEC CO LTD-H | 2359.HK | 3.39% | 142.28K | $3.7M |
| 11 | GENSCRIPT BIOTECH CORP | 1548.HK | 2.83% | 710.00K | $3.1M |
| 12 | HANSOH PHARMACEUTICAL GROUP | 3692.HK | 2.77% | 722.00K | $3.0M |
| 13 | 3SBIO INC | 1530.HK | 2.26% | 1.10M | $2.5M |
| 14 | YUNNAN BAIYAO GROUP CO LTD-A | 000538.SZ | 2.06% | 309.23K | $2.3M |
| 15 | SHANGHAI UNITED IMAGING HE-A | 688271.SS | 2.02% | 141.44K | $2.2M |
| 16 | SICHUAN KELUN-BIOTECH BIOP-H | 6990.HK | 1.99% | 32.00K | $2.2M |
| 17 | AIER EYE HOSPITAL GROUP CO-A | 300015.SZ | 1.81% | 1.61M | $2.0M |
| 18 | ZHANGZHOU PIENTZEHUANG PHA-A | 600436.SS | 1.75% | 104.23K | $1.9M |
| 19 | SICHUAN KELUN PHARMACEUTIC-A | 002422.SZ | 1.68% | 277.92K | $1.9M |
| 20 | PHARMARON BEIJING CO LTD-A | 300759.SZ | 1.66% | 256.07K | $1.8M |
| 21 | SICHUAN BIOKIN PHARMACEUTI-A | — | 1.65% | 43.31K | $1.8M |
| 22 | SINOPHARM GROUP CO-H | 1099.HK | 1.49% | 772.80K | $1.6M |
| 23 | HAISCO PHARMACEUTICAL GROU-A | 002653.SZ | 1.36% | 150.80K | $1.5M |
| 24 | WUXI XDC CAYMAN INC | 2268.HK | 1.30% | 157.00K | $1.4M |
| 25 | SHANGHAI ALLIST PHARMACEUT-A | 688578.SS | 1.21% | 76.68K | $1.3M |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | 3.74% | Paid (last 12 months) | $0.7147 |
| Frequency | Annual | SEC yield | Not provided by our data source — see the issuer page |
| Last ex-date | Dec 22, 2025 | Last payment | $0.7147 (Dec 23, 2025) |
| Growth 1Y | +289.24% | Growth 3Y / 5Y (ann.) | +309.62% / +479.88% |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Dec 22, 2025 | Dec 22, 2025 | Dec 23, 2025 | $0.7147 |
| Dec 17, 2024 | Dec 17, 2024 | Dec 18, 2024 | $0.1836 |
| Dec 18, 2023 | Dec 19, 2023 | Dec 20, 2023 | $0.1128 |
| Dec 28, 2022 | Dec 29, 2022 | Dec 30, 2022 | $0.0104 |
| Dec 29, 2021 | Dec 30, 2021 | Dec 31, 2021 | $4.0535 |
| Dec 29, 2020 | Dec 30, 2020 | Dec 31, 2020 | $0.0001 |
| Dec 27, 2019 | Dec 30, 2019 | Dec 31, 2019 | $0.0573 |
| Dec 26, 2018 | Dec 27, 2018 | Dec 28, 2018 | $0.0760 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
| Volatility 1Y / 3Y | 28.82% / 30.58% | Sharpe 1Y / 3Y | -0.109 / 0.224 |
| Max drawdown 1Y / 3Y | -30.89% / -34.03% | Sortino 1Y | -0.155 |
| Beta vs S&P 500 (3Y) | 0.464 | Correlation vs S&P 500 (1Y) | 0.295 |
| Downside deviation 1Y | 20.22% | Risk-free rate used | 3.71% (3M T-bill, FRED) |
Computed by ETF Explorer from daily dividend-adjusted closes; volatility and drawdown are annualized/period figures; S&P 500 exposure proxied by SPY. As of Aug 27, 2026. Formulas →
Liquidity
| Volume today | 15.20K | Average volume | 48.14K |
| AUM | $110.6M | Premium/Discount | +0.19% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV — an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Day | $3.5M | +3.24% | $107.1M → $110.6M |
| 1 Week | $4.4M | +4.09% | $107.5M → $110.6M |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source — review them before investing.
Latest News for KURE
No articles mention this fund directly in the last 7 days — showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.